Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
86.44 EUR | +0.91% |
|
+1.15% | +23.11% |
Jul. 10 | Citigroup Adjusts Price Target on Edwards Lifesciences to $106 From $105 | MT |
Jul. 02 | Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 35.5 and 30.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.11% | 56.51B | - | ||
+1.15% | 205B | B | ||
+4.69% | 179B | B- | ||
+31.83% | 158B | B- | ||
+33.39% | 113B | A- | ||
+2.66% | 64.93B | A- | ||
-4.03% | 46.36B | B+ | ||
-8.60% | 37.07B | A | ||
+2.35% | 36.12B | - | ||
+11.81% | 28.25B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EW Stock
- 4EW Stock
- Ratings Edwards Lifesciences Corporation